Andrew D Luster Selected Research

Chemokine CXCL10

11/2022	CXCL10 chemokine regulates heterogeneity of the CD8+ T cell response and viral set point during chronic infection.
1/2019	CXCR3 regulates CD4+ T cell cardiotropism in pressure overload-induced cardiac dysfunction.
2/2014	CXCL10 is critical for the progression and maintenance of depigmentation in a mouse model of vitiligo.
1/2009	Interferon-gamma and the interferon-inducible chemokine CXCL10 protect against aneurysm formation and rupture.
5/2006	Chemokine CXCL10 promotes atherogenesis by modulating the local balance of effector and regulatory T cells.
12/2005	Interferon-inducible protein 10, but not monokine induced by gamma interferon, promotes protective type 1 immunity in murine Klebsiella pneumoniae pneumonia.
9/2005	Anti-interferon-inducible chemokine, CXCL10, reduces colitis by impairing T helper-1 induction and recruitment in mice.
9/2005	Neuronal CXCL10 directs CD8+ T-cell recruitment and control of West Nile virus encephalitis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Andrew D Luster Research Topics

Disease

55	Inflammation (Inflammations) 11/2020 - 05/2002
25	Infections 01/2020 - 04/2002
15	Asthma (Bronchial Asthma) 11/2019 - 05/2002
13	Neoplasms (Cancer) 10/2022 - 07/2003
11	Arthritis (Polyarthritis) 10/2019 - 04/2006
8	Fibrosis (Cirrhosis) 01/2017 - 10/2004
6	Autoimmune Diseases (Autoimmune Disease) 01/2022 - 12/2003
6	Pulmonary Fibrosis (Fibrosing Alveolitis) 12/2013 - 10/2004
6	Pneumonia (Pneumonitis) 12/2013 - 05/2002
6	Atherosclerosis 02/2008 - 12/2002
5	Systemic Lupus Erythematosus (Libman-Sacks Disease) 01/2022 - 02/2005
4	HIV Infections (HIV Infection) 01/2016 - 01/2003
4	Virus Diseases (Viral Diseases) 01/2016 - 09/2006
4	Respiratory Hypersensitivity 12/2013 - 04/2005
4	Bronchiolitis 01/2013 - 07/2005
4	Alzheimer Disease (Alzheimer's Disease) 12/2008 - 01/2002
3	Hypersensitivity (Allergy) 10/2022 - 05/2007
3	Rheumatic Diseases (Rheumatism) 07/2020 - 02/2005
3	Rheumatoid Arthritis 07/2020 - 01/2018
3	Vasculitis (Vasculitides) 07/2020 - 04/2017
3	Vitiligo 01/2020 - 02/2014
3	Melanoma (Melanoma, Malignant) 01/2019 - 01/2002
3	Multiple Sclerosis 06/2013 - 05/2002
3	Lung Injury 01/2013 - 01/2008
3	Lung Diseases (Lung Disease) 06/2011 - 12/2005
3	Lyme Disease (Disease, Lyme) 01/2010 - 09/2007
3	Ischemia 09/2007 - 03/2006
2	Persistent Infection 11/2022 - 08/2007
2	Respiratory Distress Syndrome (Acute Respiratory Distress Syndrome) 12/2019 - 01/2013
2	Cerebral Malaria 12/2019 - 03/2008
2	Colorectal Neoplasms (Colorectal Cancer) 08/2017 - 01/2017
2	Myocardial Infarction 10/2013 - 11/2009
2	Nephritis 09/2013 - 06/2008
2	Obesity 10/2009 - 02/2008
2	Abdominal Aortic Aneurysm 01/2009 - 07/2007
2	Atherosclerotic Plaque (Atheroma) 01/2009 - 07/2005
2	Eosinophilia 01/2009 - 05/2002
2	Erythema 01/2008 - 09/2007
2	Colitis 06/2007 - 09/2005
2	Graft vs Host Disease (Graft-Versus-Host Disease) 12/2005 - 07/2004
2	Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental) 01/2004 - 05/2002
2	Amyloid Plaque 06/2003 - 01/2002

Drug/Important Bio-Agent (IBA)

63	ChemokinesIBA 11/2021 - 04/2002
22	LigandsIBA 01/2021 - 12/2003
21	Chemokine ReceptorsIBA 12/2019 - 12/2004
19	CytokinesIBA 10/2017 - 05/2002
14	Proteins (Proteins, Gene)FDA Link 01/2019 - 05/2002
13	Chemotactic FactorsIBA 10/2019 - 04/2002
13	Leukotriene B4IBA 01/2018 - 10/2003
11	AutoantibodiesIBA 01/2022 - 02/2005
10	AllergensIBA 11/2020 - 04/2005
10	AntigensIBA 01/2018 - 01/2006
8	Chemokine CXCL10IBA 11/2022 - 09/2005
7	CXC ChemokinesIBA 07/2014 - 12/2003
6	LipidsIBA 10/2017 - 09/2004
6	Antiviral Agents (Antivirals)IBA 01/2016 - 01/2003
5	Interferon-gamma (Interferon, gamma)IBA 01/2017 - 10/2004
5	InterferonsIBA 01/2016 - 09/2005
5	Bleomycin (Blenoxane)FDA LinkGeneric 05/2011 - 10/2004
4	Antigen-Antibody Complex (Immune Complex)IBA 10/2019 - 02/2005
4	CollagenIBA 01/2017 - 11/2009
4	Biomarkers (Surrogate Marker)IBA 01/2017 - 02/2004
4	Leukotriene B4 Receptors (Leukotriene B4 Receptor)IBA 01/2016 - 03/2006
4	LeukotrienesIBA 04/2015 - 09/2004
4	OvalbuminIBA 01/2013 - 01/2006
4	Apolipoproteins E (ApoE)IBA 01/2009 - 07/2005
4	Messenger RNA (mRNA)IBA 01/2008 - 09/2005
3	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 08/2017 - 06/2006
3	Transcription Factors (Transcription Factor)IBA 01/2017 - 11/2006
3	Arachidonate 5-Lipoxygenase (5 Lipoxygenase)IBA 12/2013 - 07/2005
3	DNA (Deoxyribonucleic Acid)IBA 09/2013 - 02/2005
3	lysophosphatidic acidIBA 05/2013 - 01/2008
3	indium-bleomycinIBA 12/2010 - 10/2004
3	Amyloid beta-PeptidesIBA 06/2003 - 01/2002
2	Scavenger Receptors (Scavenger Receptor)IBA 01/2022 - 01/2002
2	IntegrinsIBA 01/2020 - 01/2019
2	Complement C5a (Complement 5a)IBA 10/2019 - 01/2017
2	CXCR3 ReceptorsIBA 01/2019 - 03/2006
2	Complement System Proteins (Complement)IBA 01/2018 - 10/2017
2	Biological ProductsIBA 01/2018 - 10/2017
2	Immunoglobulin G (IgG)IBA 01/2018 - 06/2008
2	InterleukinsIBA 05/2017 - 09/2005
2	MucinsIBA 10/2016 - 01/2013
2	VaccinesIBA 01/2016 - 04/2015
2	plerixafor FDA Link 01/2014 - 11/2003
2	Interleukin-5 (Interleukin 5)IBA 12/2013 - 06/2006
2	EnzymesIBA 10/2012 - 07/2007
2	Lysophosphatidic Acid ReceptorsIBA 05/2011 - 01/2008
2	GlycosaminoglycansIBA 06/2010 - 01/2008
2	AdiponectinIBA 10/2009 - 02/2008
2	ApolipoproteinsIBA 01/2009 - 02/2008
2	LipopolysaccharidesIBA 02/2008 - 01/2008
2	Interleukin-10 (Interleukin 10)IBA 01/2008 - 09/2005
2	Interleukin-4 (Interleukin 4)IBA 06/2006 - 05/2002
2	Interleukin-13IBA 06/2006 - 04/2005
2	NucleoproteinsIBA 12/2005 - 02/2005

Therapy/Procedure

12	Therapeutics 08/2017 - 09/2005
4	Immunotherapy 10/2022 - 12/2005
4	Lung Transplantation 01/2013 - 07/2005
2	Transplantation 01/2014 - 06/2006